• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Analyst Expectations for DICE Therapeutics's Future

    6/20/23 4:02:20 PM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DICE alert in real time by email

    Over the past 3 months, 7 analysts have published their opinion on DICE Therapeutics (NASDAQ:DICE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 3 0 4 0 0
    Last 30D 0 0 3 0 0
    1M Ago 1 0 1 0 0
    2M Ago 1 0 0 0 0
    3M Ago 1 0 0 0 0

    According to 7 analyst offering 12-month price targets in the last 3 months, DICE Therapeutics has an average price target of $52.71 with a high of $71.00 and a low of $38.00.

    Below is a summary of how these 7 analysts rated DICE Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

    price target chart

    This current average represents a 5.32% decrease from the previous average price target of $55.67.

    Stay up to date on DICE Therapeutics analyst ratings.

    How Are Analyst Ratings Determined?

    Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

    Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $DICE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DICE

    DatePrice TargetRatingAnalyst
    5/24/2023$38.00Equal Weight
    Wells Fargo
    5/22/2023$71.00Buy
    Canaccord Genuity
    3/31/2023$56.00Buy
    Needham
    3/1/2023Outperform
    TD Cowen
    3/1/2023Outperform
    Cowen
    11/15/2022$65.00Buy
    Guggenheim
    9/14/2022$36.00Overweight
    Cantor Fitzgerald
    9/7/2022$37.00Buy
    Stifel
    More analyst ratings

    $DICE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ra Capital Management, L.P.

    4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

    8/9/23 5:00:37 PM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Tetlow Sharon returned 49,841 shares to the company, closing all direct ownership in the company

    4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

    8/9/23 4:38:19 PM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Simson Jake

    4 - DICE Therapeutics, Inc. (0001645569) (Issuer)

    8/9/23 4:36:43 PM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DICE
    SEC Filings

    View All

    SEC Form 15-12G filed by DICE Therapeutics Inc.

    15-12G - DICE Therapeutics, Inc. (0001645569) (Filer)

    8/21/23 8:00:26 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by DICE Therapeutics Inc.

    EFFECT - DICE Therapeutics, Inc. (0001645569) (Filer)

    8/11/23 12:15:08 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by DICE Therapeutics Inc.

    S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)

    8/9/23 9:47:55 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DICE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on DICE Therapeutics with a new price target

    Wells Fargo initiated coverage of DICE Therapeutics with a rating of Equal Weight and set a new price target of $38.00

    5/24/23 7:49:57 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on DICE Therapeutics with a new price target

    Canaccord Genuity initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $71.00

    5/22/23 7:17:25 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on DICE Therapeutics with a new price target

    Needham initiated coverage of DICE Therapeutics with a rating of Buy and set a new price target of $56.00

    3/31/23 7:20:41 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DICE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly Completes Acquisition of DICE Therapeutics

    INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

    8/9/23 9:02:00 AM ET
    $DICE
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly Announces Extension of Tender Offer to Acquire DICE

    INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ:DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. The proposed acquisition is expected to close in the third q

    7/25/23 6:55:00 AM ET
    $DICE
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

    NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m

    6/24/23 8:11:00 PM ET
    $BG
    $DICE
    $KDNY
    Packaged Foods
    Consumer Staples
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DICE
    Financials

    Live finance-specific insights

    View All

    Lilly Completes Acquisition of DICE Therapeutics

    INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new

    8/9/23 9:02:00 AM ET
    $DICE
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

    Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008 DC-806 was well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients with a robust PK profile and clear pharmacodynamic effects on two distinct biomarkers at both high and low doses of DC-806 Data supports further development of DC-806 as potential best-in-class oral agent for psoriasis; DC-806 is expected to advance into a Phase 2b clinical trial in the first half of 2023 Company to host conference cal

    10/11/22 7:00:00 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DICE
    Leadership Updates

    Live Leadership Updates

    View All

    ShouTi Appoints Sharon Tetlow to Board of Directors

    ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today announced the appointment of Sharon Tetlow to the company's board of directors. Ms. Tetlow will also serve as chair of the audit committee. "On behalf of the board and management team at ShouTi, I am pleased to welcome Sharon to the board," said Daniel Welch, Chairman of the Board, ShouTi. "Sharon is an accomplished life sciences finance executive whose deep financial strategy and compliance expertise will be instrumental in leading our audit committee. With an outstanding track record of advising biopharmaceutical companies, Sharon's perspectiv

    3/29/22 8:00:00 AM ET
    $CBIO
    $DICE
    $VALN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    DICE Therapeutics Expands Management Team and Board of Directors

    Mary Riley, J.D., appointed as general counselLisa Bowers, MHSA, and Mittie Doyle, M.D., FACR, join board of directors SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (NASDAQ:DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE's board of directors. Concurrently, Stephen Zachary, Ph.D., will be stepping down from the Company's board. "Mary, Lisa and Mittie are e

    3/28/22 4:05:00 PM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DICE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

    SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

    8/9/23 5:00:12 PM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by DICE Therapeutics Inc. (Amendment)

    SC 13G/A - DICE Therapeutics, Inc. (0001645569) (Subject)

    7/10/23 10:20:11 AM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)

    SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)

    6/23/23 5:10:56 PM ET
    $DICE
    Biotechnology: Pharmaceutical Preparations
    Health Care